Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
SGEN's Cash-to-Debt is ranked higher than
98% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. SGEN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.76
SGEN's Equity-to-Asset is ranked higher than
62% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGEN: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
SGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.63 Max: 0.96
Current: 0.76
0.36
0.96
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
99% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SGEN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 27.64
Beneish M-Score: -2.63
WACC vs ROIC
15.83%
-262.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -48.22
SGEN's Operating Margin % is ranked higher than
58% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. SGEN: -48.22 )
Ranked among companies with meaningful Operating Margin % only.
SGEN' s Operating Margin % Range Over the Past 10 Years
Min: -260.49  Med: -49.69 Max: -23.35
Current: -48.22
-260.49
-23.35
Net Margin % -47.38
SGEN's Net Margin % is ranked higher than
57% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. SGEN: -47.38 )
Ranked among companies with meaningful Net Margin % only.
SGEN' s Net Margin % Range Over the Past 10 Years
Min: -242.65  Med: -48.72 Max: -23.22
Current: -47.38
-242.65
-23.22
ROE % -32.34
SGEN's ROE % is ranked higher than
54% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. SGEN: -32.34 )
Ranked among companies with meaningful ROE % only.
SGEN' s ROE % Range Over the Past 10 Years
Min: -128.57  Med: -35.29 Max: -21.23
Current: -32.34
-128.57
-21.23
ROA % -24.83
SGEN's ROA % is ranked higher than
56% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. SGEN: -24.83 )
Ranked among companies with meaningful ROA % only.
SGEN' s ROA % Range Over the Past 10 Years
Min: -50.86  Med: -18.13 Max: -12
Current: -24.83
-50.86
-12
ROC (Joel Greenblatt) % -252.78
SGEN's ROC (Joel Greenblatt) % is ranked higher than
56% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. SGEN: -252.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -903.49  Med: -405.77 Max: -178.02
Current: -252.78
-903.49
-178.02
3-Year Revenue Growth Rate 10.30
SGEN's 3-Year Revenue Growth Rate is ranked higher than
61% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SGEN: 10.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 7.7  Med: 35.05 Max: 148.1
Current: 10.3
7.7
148.1
3-Year EBITDA Growth Rate 25.70
SGEN's 3-Year EBITDA Growth Rate is ranked higher than
75% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. SGEN: 25.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 2.5 Max: 25.7
Current: 25.7
-30.1
25.7
3-Year EPS without NRI Growth Rate 25.20
SGEN's 3-Year EPS without NRI Growth Rate is ranked higher than
77% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. SGEN: 25.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34  Med: -1.3 Max: 27.9
Current: 25.2
-34
27.9
GuruFocus has detected 4 Warning Signs with Seattle Genetics Inc SGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SGEN's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SGEN Guru Trades in Q3 2016

Paul Tudor Jones 8,729 sh (New)
Manning & Napier Advisors, Inc 257,580 sh (+12.81%)
PRIMECAP Management 13,420,237 sh (-0.70%)
Columbia Wanger 682,974 sh (-52.19%)
George Soros 4,347 sh (-70.43%)
Joel Greenblatt 8,242 sh (-72.60%)
» More
Q4 2016

SGEN Guru Trades in Q4 2016

Ray Dalio 163,107 sh (New)
Jim Simons 253,313 sh (New)
Joel Greenblatt 12,900 sh (+56.52%)
Columbia Wanger 760,744 sh (+11.39%)
George Soros Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 13,230,162 sh (-1.42%)
Manning & Napier Advisors, Inc 140,670 sh (-45.39%)
» More
Q1 2017

SGEN Guru Trades in Q1 2017

Steven Cohen 469,625 sh (New)
Paul Tudor Jones 4,733 sh (New)
Joel Greenblatt 86,842 sh (+573.19%)
Jim Simons Sold Out
Ray Dalio Sold Out
PRIMECAP Management 13,182,312 sh (-0.36%)
Columbia Wanger 592,582 sh (-22.10%)
Manning & Napier Advisors, Inc 100,385 sh (-28.64%)
» More
Q2 2017

SGEN Guru Trades in Q2 2017

Jim Simons 6,613 sh (New)
Caxton Associates 5,200 sh (New)
Ray Dalio 106,760 sh (New)
Paul Tudor Jones 24,739 sh (+422.69%)
Manning & Napier Advisors, Inc Sold Out
PRIMECAP Management 12,958,975 sh (-1.69%)
Columbia Wanger 413,994 sh (-30.14%)
Joel Greenblatt 31,269 sh (-63.99%)
Steven Cohen 120,000 sh (-74.45%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Reduce -63.99%0.04%$51.39 - $68.3 $ 63.860%31,269
Joel Greenblatt 2017-03-31 Add 573.19%0.06%$53 - $68.91 $ 63.862%86,842
Joel Greenblatt 2016-12-31 Add 56.52%$49.93 - $73.71 $ 63.866%12,900
George Soros 2016-12-31 Sold Out 0.01%$49.93 - $73.71 $ 63.866%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:HKSE:01177, NAS:ALKS, NAS:EXEL, NAS:TSRO, NAS:IONS, NAS:JAZZ, NAS:BIVV, NAS:BLUE, HKSE:02269, NAS:NBIX, NAS:UTHR, XAMS:GLPG, NAS:KITE, NAS:ALNY, NAS:ACAD, NAS:JUNO, NAS:TECH, XKRX:128940, NAS:PBYI, OSTO:SOBI » details
Traded in other countries:SGT.Germany,
Headquarter Location:USA
Seattle Genetics Inc is a development-stage biotech company. It develops monoclonal antibody-based therapies. Its lead product, Adcetris, has received approval for relapsed/refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma.

Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for relapsed/refractory and post-consolidation Hodgkin lymphoma and anaplastic large-cell lymphoma, and the company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Top Ranked Articles about Seattle Genetics Inc

Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Green Monday for Capital Markets Around the Globe Seattle Genetics rises in premarket trading
The U.S. stock market indexes opened in green Monday. The S&P 500, the Nasdaq and the Dow Jones started the week with gains. Read more...
Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN

NEW YORK, March 08, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc. (“Seattle Genetics”) (NASDAQ:SGEN) between October 27, 2016 and December 23, 2016.      You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Washington. If you purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/seattle-genetics-inc or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that throughout the class period, Seattle Genetics made false and/or misleading statements and/or failed to disclose that: (a) its product in development, vadastuximab talirine, presents a significant risk of fatal hepatoxicity; (b) as such, Seattle Genetics had overstated the viability of vadastuximab talirine as a treatment for acute myeloid leukemia; and (c) as a result, the Company’s statements were materially false and misleading at all relevant times. On December 27, 2016, Seattle Genetics issued a press release announcing that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of vadastuximab talirine. If you suffered a loss in Seattle Genetics you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Seattle Genetics Inc. (SGEN) To Contact The Firm

STEVENSON, Md., March 05, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Seattle Genetics Inc. (NASDAQ:SGEN) (“Seattle Genetics” or the “Company”) securities during the period between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 13, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Seattle Genetics securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Seattle Genetics’ vadastuximab talirine presents a significant risk of fatal hepatotoxicity and that the Company had overstated the viability of vadastuximab talirine as a treatment for acute myeloid leukemia (“AML”). According to the complaint, following a December 27, 2016 press release announcing that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of vadastuximab talirine to evaluate the potential risk of hepatotoxicity, the value of Seattle Genetics shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in Seattle Genetics securities purchased on or after October 27, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
IMPORTANT SEATTLE GENETICS INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the Western District of Washington against Seattle Genetics Inc.

Rapidly Approaching Lead Plaintiff Deadline is March 13, 2017

NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (“Seattle Genetics” or the “Company”) (NASDAQ:SGEN) and certain of its officers.  The class action, filed in United States District Court for the Western District of Washington is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”).
Investors who have incurred losses in shares of Seattle Genetics Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com. If you have purchased shares of Seattle Genetics Inc. within the class period and would like to assist with the litigation process, you may, no later than March 13, 2017, request that the Court appoint you lead plaintiff of the proposed class. Seattle Genetics develops and commercializes targeted therapies for the treatment of cancer worldwide.  Among the Company’s products in development is SGN-CD33A (vadastuximab talirine).  Throughout the Class Period,  vadastuximab talirine was  in  clinical  trials for  various  applications,  including,  in relevant part: (i) a Phase 1/2  trial in patients with acute myeloid leukemia (AML) as a pre-conditioning regimen prior to an allogenic stem cell transplant and as a maintenance therapy following transplant; (ii) a Phase 1 trial evaluating vadastuximab talirine monotherapy, including a subset of older  AML patients in combination with hypomethylating agents; and (iii) a Phase 1 trial evaluating vadastuximab talirine combination treatment with 7 3 chemotherapy in newly diagnosed younger AML patients. The filed Complaint  alleges  that throughout the Class  Period, Defendants  made materially false and/or misleading statements,  as well as failed to  disclose  material  adverse  facts  about the  Company’s  business, operations, and prospects.  Specifically, Defendants made  false and/or misleading  statements and/or  failed  to  disclose  that: (i) vadastuximab  talirine presents  a significant risk of fatal hepatotoxicity;  (ii) as such, Seattle Genetics had overstated the viability of vadastuximab talirine as an  AML treatment;  and (iii) as a result of the foregoing, Seattle Genetics’ public statements  were materially false and misleading at all relevant times.  On December 27,  2016, Seattle  Genetics issued a  press release  and filed  a Form  8-K with the  Securities and Exchange Commission (SEC) announcing that  the Food  and Drug Administration had (FDA) placed a clinical  hold or partial  clinical hold  on several  early  stage  trials  of  the  Company’s  experimental  cancer  drug,  vadastuximab talirine,  to evaluate the potential risk of hepatotoxicity. On this news, Seattle Genetics’ share price fell $9.50, or 15.36 %, to close at $52.36 on December 27, 2016. Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation. If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com. ## Follow the firm and learn about newly filed cases on Twitter and Facebook. ## Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

Read more...
Insiders Buy Herbalife, Sell MasterCard The largest insiders' buys and sales of the week
The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$200,000+” duration to October 2016 and November 2016 and All Insider Sales to “$5,000,000+”. Read more...

Ratios

vs
industry
vs
history
PB Ratio 15.93
SGEN's PB Ratio is ranked lower than
87% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. SGEN: 15.93 )
Ranked among companies with meaningful PB Ratio only.
SGEN' s PB Ratio Range Over the Past 10 Years
Min: 3.06  Med: 10.04 Max: 35.99
Current: 15.93
3.06
35.99
PS Ratio 21.11
SGEN's PS Ratio is ranked lower than
60% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. SGEN: 21.11 )
Ranked among companies with meaningful PS Ratio only.
SGEN' s PS Ratio Range Over the Past 10 Years
Min: 10.06  Med: 18.87 Max: 45.33
Current: 21.11
10.06
45.33
EV-to-EBIT -41.97
SGEN's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. SGEN: -41.97 )
Ranked among companies with meaningful EV-to-EBIT only.
SGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -102.6  Med: -28.95 Max: -4.7
Current: -41.97
-102.6
-4.7
EV-to-EBITDA -46.38
SGEN's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. SGEN: -46.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -120.2  Med: -32.2 Max: -4.9
Current: -46.38
-120.2
-4.9
EV-to-Revenue 20.20
SGEN's EV-to-Revenue is ranked lower than
55% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. SGEN: 20.20 )
Ranked among companies with meaningful EV-to-Revenue only.
SGEN' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.4  Med: 16.9 Max: 44.7
Current: 20.2
7.4
44.7
Current Ratio 4.47
SGEN's Current Ratio is ranked higher than
53% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SGEN: 4.47 )
Ranked among companies with meaningful Current Ratio only.
SGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.65  Med: 5.23 Max: 30.03
Current: 4.47
2.65
30.03
Quick Ratio 3.97
SGEN's Quick Ratio is ranked higher than
52% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. SGEN: 3.97 )
Ranked among companies with meaningful Quick Ratio only.
SGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.29  Med: 5.04 Max: 30.03
Current: 3.97
2.29
30.03
Days Inventory 530.39
SGEN's Days Inventory is ranked lower than
95% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. SGEN: 530.39 )
Ranked among companies with meaningful Days Inventory only.
SGEN' s Days Inventory Range Over the Past 10 Years
Min: 442.93  Med: 547.11 Max: 639.76
Current: 530.39
442.93
639.76
Days Sales Outstanding 61.22
SGEN's Days Sales Outstanding is ranked higher than
55% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. SGEN: 61.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40  Med: 61.69 Max: 562.77
Current: 61.22
40
562.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.10
SGEN's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. SGEN: -5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -113.5  Med: -12.05 Max: -2.2
Current: -5.1
-113.5
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 33.97
SGEN's Price-to-Net-Cash is ranked lower than
83% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. SGEN: 33.97 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGEN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.12  Med: 12.63 Max: 284.71
Current: 33.97
2.12
284.71
Price-to-Net-Current-Asset-Value 21.15
SGEN's Price-to-Net-Current-Asset-Value is ranked lower than
79% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. SGEN: 21.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGEN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.09  Med: 10.11 Max: 447
Current: 21.15
2.09
447
Price-to-Tangible-Book 15.93
SGEN's Price-to-Tangible-Book is ranked lower than
82% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. SGEN: 15.93 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.78  Med: 7.45 Max: 33.75
Current: 15.93
1.78
33.75
Price-to-Median-PS-Value 1.12
SGEN's Price-to-Median-PS-Value is ranked higher than
53% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. SGEN: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.13 Max: 33.53
Current: 1.12
0.55
33.53
Earnings Yield (Greenblatt) % -2.39
SGEN's Earnings Yield (Greenblatt) % is ranked higher than
65% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. SGEN: -2.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -21.4  Med: -3.45 Max: -1
Current: -2.39
-21.4
-1

More Statistics

Revenue (TTM) (Mil) $428.94
EPS (TTM) $ -1.43
Beta2.25
Short Percentage of Float15.18%
52-Week Range $45.31 - 75.36
Shares Outstanding (Mil)143.03

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 446 532 705 958
EPS ($) -1.60 -1.15 -0.15 1.05
EPS without NRI ($) -1.60 -1.15 -0.15 1.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}